News
Imagine treating a genetic disease not by managing symptoms for life, but by correcting the underlying genetic error itself. Inventors at NIH are advancing that vision with a gene editing technology designed to deliver highly precise genetic corrections, opening new possibilities for therapies that
The NIH Technology Transfer Program has won the Licensing Executive Society’s Deals of Distinction award for 2022. The Deals of Distinction Award is given to an outstanding licensing deal from the past year. Steve Ferguson, Special Advisor at the NIH Office of Technology Transfer, recently attended
Cell Lines for the Study of Neurodegenerative Disorders and their Treatments Available for Licensing
Gaucher disease is a rare and heterogenous disorder caused by inherited Glucocerebrosidase (GBA1) genetic mutations. The National Human Genome Research Institute (NHGRI) has six cell lines available for licensing for the study of GBA1 mutations. These cell lines can be used to study the defects in
It’s almost the new year – get ahead on your planning with the Federal Laboratory Consortium (FLC)’s free 2023 planner! This planner features images submitted from a variety of federal labs, showcasing a new technology each month. The FLC planner is a great way to track all of your important dates